Answers are grounded in this paper and cite their sources.
Chronic pulmonary diseases are often associated with high morbidity and/or mortality, and many lack effective therapies. Direct delivery of antisense oligonucleotides (ASOs) to the lung shows promise for the treatment of pulmonary diseases. Despite their overall low risk profiles, systemically delivered ASOs can be associated with pro-inflammatory responses including activation of the alternative complement pathway, particularly near administration sites. Nonhuman primates (NHPs) and Beagle dogs have both been used in ASO toxicity studies, but comparative suitability of these species for ASO safety assessment has not been established. Herein, we compare the tolerability of a phosphorothioate (PS) gapmer ASO in these species after dosing with a nebulized ASO delivered by inhalation at 15 mg/kg once weekly for 13 weeks via face mask. Although lung concentrations of ASO were similar in cynomolgus monkeys and Beagle dogs, ASO inhalation was associated with greater pro-inflammatory responses in the monkey. Anti-drug antibody production, C-reactive protein elevation, complement activation, increased bronchoalveolar lavage fluid cellularity, increased lung weights, and microscopic evidence of pulmonary inflammation were present in the monkey but not the dog. Therefore, although NHPs and dogs can be used in toxicity testing of inhaled ASOs, NHPs exhibit a predisposition to complement activation and development of pulmonary inflammation.
No takes yet. Share an insight, caveat, or question.
Berman-Booty et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: